Maxwell Biosciences

Destroys Most Infections with One Nontoxic Molecule. 10 Year FDA Exclusivity on All-Cause Pneumonia.

https://wefunder.com/maxwell.biosciences

Total raised on Wefunder: 351500

Total investors: 32

Quick facts

  • FDA QIDP in bacterial & fungal pneumonia: FDA Fast Track, Priority Review, 10-yr exclusivity
  • Govt-sponsored primate study: MRSA & Candida cleared from the head in 3 days, no toxicity
  • $69M+ in funding & grants; government backing from US, Australia, India, S. Korea & Japan
  • 7 signed U.S. military R&D agreements (CRADAs) + a $3M U.S. Army MTEC award, all non-dilutive
  • Novel membrane + DNA/RNA mechanism showed no bacterial resistance across 30 lab passages
  • Backed by 500+ peer-reviewed published studies; published in-vivo efficacy, safety and no resistance
  • A platform, not one drug: AI designs Claromers that mimic the body's own immune peptides
  • Board includes Eli Lilly President, Ret. U.S. Army biodefense commanding General, former Congressman

Team profiles

Featured investor profiles

Maxwell Biosciences

Destroys Most Infections with One Nontoxic Molecule. 10 Year FDA Exclusivity on All-Cause Pneumonia.

Never miss an update

  • Join the Maxwell Biosciences community. Follow their journey as they grow.
  • Stay in the loop if they ever decide to raise a round.

Highlights

VC-Backed

Raised $250K or more from a venture firm

VC-Backed

Notable Angel

Raised $25k or more from a notable angel investor

Notable Angel

Repeat Founder

Started a prior company with $2M+ in funding or revenue

Repeat Founder
1
FDA QIDP in bacterial & fungal pneumonia: FDA Fast Track, Priority Review, 10-yr exclusivity
2
Govt-sponsored primate study: MRSA & Candida cleared from the head in 3 days, no toxicity
3
$69M+ in funding & grants; government backing from US, Australia, India, S. Korea & Japan
4
7 signed U.S. military R&D agreements (CRADAs) + a $3M U.S. Army MTEC award, all non-dilutive

Related company links

Featured Investors

Team


Pitch Deck

1 / —

Memo

One drug for many bugs. FDA designated and prioritized. Backed by multiple governments. It cleared drug-resistant, deadly bacterial and fungal infections from nonhuman primates with a single molecule in 3 days flat. Zero toxicity. Zero microbial resistance in 30+ rounds of testing. The first molecule of its kind to earn dual FDA FAST TRACK and Priority Review status. FDA QIDP designated for bacterial or fungal pneumonia (all cause) and comes with a 10-year market exclusivity upon approval. With revenue estimated at billions per year by Ernst & Young, a 10 year market exclusivity in all-case pneumonia comes with an estimated value of $60-100 billion.

The Problem

Our system is broken. The current state of healthcare, medication, food, insurance, and our environment is keeping us chronically ill. Our mission is to make people healthy.

You've probably had an infection that antibiotics couldn't fully clear, or it did and you’re left with a destroyed gut-microbiome, impacting your overall health. Multiply that by hundreds of millions of people, and you're looking at the biggest unmet need in healthcare today and it's getting worse on three fronts at once.

  1. Bacteria are winning. Drug-resistant infections are projected to kill 10 million people a year by 2050 — more than cancer does today. Every new antibiotic takes about a decade to develop, and many lose their effectiveness within a few years of hitting the market. Many bacteria have no FDA approved drugs, like Lymes Disease mycobacteria.
  2. Viruses have outrun our capacity to vaccinate. Vaccines are pathogen-specific and slow to develop against new threats, and as the last few years made clear, populations are increasingly resistant to accept broad or mandatory vaccination. That leaves millions exposed with no broad-spectrum option after exposure, whether it's a new pandemic or lingering viral infections, like Epstein-Barr, now linked to long-term conditions such as Long COVID and chronic fatigue.
  3. Fungal remedies are rare and dangerous. Effective antifungals hardly exist, and the ones that do are toxic and slow to clear infection. Resistant threats like Candida auris spread through hospitals worldwide.

And the human cost isn't abstract. In India, more than half of newborn sepsis cases, a leading cause of infant death, are now multi-drug resistant. Doctors are running out of options for the most vulnerable patients on Earth.

The current model — one drug for one bug — require diagnostics hundreds or thousands of times more expensive than the treatment and cannot keep up with pathogens that mutate faster than we can develop new medicine against them. At Maxwell Biosciences, we’ve built something better and it's already proven in gold standard animal models.


The Vision

Your body already knows how to fight all three threats at once. Broad-spectrum, antimicrobial peptides like LL-37 are part of your innate immune system's first line of defense. LL-37 can take down bacteria, fungi and viruses simultaneously, often before you even feel sick. The problem is peptides are not stable and fall apart in the body. almost immediately.

Maxwell has the ability to mimic any of the 10,000+ peptides in the human body.

We take what the immune system already does best and make it safe, effective (therapeutically or preventatively) and durable enough to manufacture, ship and deliver. Rather than prescribing one drug for only one infection using lengthy diagnostic testing, Maxwell’s broad-spectrum platform addresses many infectious disease needs all at once often with a single molecule, such as the next viral pandemic, bacterial food illness or fungal outbreak. Maxwell's vision is to create health for the world, safely and affordably.

The Solution: Claromers®

Maxwell's core innovation is a chemistry breakthrough and game-changing solution: swap the fragile carbon bond of a natural immune peptide for nitrogen to make it more stable than a naturally-existing peptide. Maxwell calls these peptide mimics Claromers®. Maxwell is testing safety and efficacy of multiple Claromers to determine which would make the best therapeutics. A proprietary, AI-driven platform designs and screens these molecules—so Maxwell isn't developing one therapeutic, but a whole library and pipeline of them to restore immunity, repair tissue, enhance physical performance and extend healthspan.

Maxwell’s lead FDA candidates are the Claromers® that mimic the immune peptide LL-37’s pathogen-killing function but survive in the body, show no resistance, need no refrigeration, can be manufactured at scale and well below the cost of existing solutions—even generics.

Claromers® have shown potent activity against a strikingly broad range of threats: drug-resistant bacteria, fungi, mold, yeast and enveloped viruses including pan-coronavirus, pan-influenza, pan-herpes, including Epstein Barr Virus, RSV and many others—even fully suppressing Ebola virus in testing. Claromers® have been well tolerated at over 100 times the relevant therapeutic dose in preclinical tissue studies, with no toxicity.

Claromers® beat superbugs at their own game.

Maxwell Biosciences is not only mimicking nature; we’re enhancing it to combat the global threat of infectious diseases with unparalleled precision and durability.


Traction

Maxwell’s technology is validated by multiple sources: governments, investors and over 500 peer-reviewed scientific study articles.

Maxwell's technology was originally incubated with support from DARPA, the Department of Energy and the NIH—and that government backing has only deepened: $35M+ in government support to date and the momentum is accelerating. This includes programs sponsored by five governments (the US, Australia, India, South Korea, and Japan), seven signed U.S. military research agreements (CRADAs), and a $3M U.S. Army MTEC award, all non-dilutive to investors. The board includes a former U.S. Army biodefense Commanding General, a former U.S. Congressman and a former President of Eli Lilly, and a former pharmaceutical company CEO.

In May 2026, the FDA granted Maxwell's lead pneumonia candidate (MXB-22,510-SC) Qualified Infectious Disease Product (QIDP) designation for all-cause pneumonia. This is a rare status reserved for therapeutics targeting deadly or serious drug-resistant bacterial or fungal infections. It's the first dual-class designation (effective against both bacterial and fungal pneumonia) in FDA history. Unprompted by Maxwell, the FDA proactively encouraged this broad scope during review. QIDP status brings FDA FAST TRACK upon request and FDA Priority Review (cutting the FDA's review target from 10 months to 6) and up to 10 years of market exclusivity on approval.

In an official study sponsored by the Government of India's ICMR (equivalent to U.S. NIH), Maxwell’s lead Claromer®, MXB-22,510, cleared drug-resistant MRSA and Candida albicans sinus/head infections from nonhuman primates within three days, with no signs of toxicity.

MXB-22,510 is Maxwell’s lead FDA candidate to target pneumonia, invasive head and sinus infections, Long Covid and all-cause pneumonia. The U.S. military is considering its use in a variety of delivery mechanisms (topical, oral, etc.) for biodefense, like accelerated wound healing, prevention of surgical infections, severe diarrhea, and stockpiling for future pandemics and rare tropical diseases. Governments around the world are interested in its use for livestock health and wellness, namely to fight Brucella bacteria in large animals, which impacts fertility and milk supply in cattle and horses.

Near term, instant revenue-generating, Fortune 500 partnerships are underway and already generating revenue with Claromer® MXB-22,816 (not tested on animals) in co-development in many consumer, non-clinical products like deodorants, coatings, food safety, hospital surface antiseptics, cosmetics, personal care products, dental care products and more. Generating revenue prior to FDA trials is one of the many aspects that sets Maxwell apart from other biotechnology companies.

Those cosmetics and consumer product partnerships lead to fast money, and -- in parallel -- FDA approval for large medical applications drives large revenue. In the U.S. alone, Ernst & Young-Parthenon estimates the year-one pneumonia drug market at at least $650 - 700M USD a year, with approximately 1.3 million confirmed cases treatable with MXB-22,510-SC. Globally, the numbers are staggering and that just grows over time with an FDA approval-triggered 10 year market exclusivity.

The Raise

The financial precedent is well established: QIDP-backed anti-infectives have repeatedly sold for billions. Merck acquired Cubist for $9.5B and Cidara for $9.2B. QIDP assets typically reach market within about five years of designation. EY-Parthenon is now coordinating Maxwell's pre-IPO round, with a potential IPO targeted within the next 2 years.

Maxwell is raising a convertible note at a $282M valuation cap, 20% discount, and 8% interest (maturing 36 months from issuance), with a $50,000 minimum investment. The valuation cap was set before the FDA's QIDP announcement. This is likely the last round available to angels and family offices before an institutional and strategic Series A at a significantly higher valuation.

Proceeds go primarily to FDA requirements for human trials: preclinical studies (including toxicology) and manufacturing to produce and supply Claromers® for these studies. Funding also covers the AI platform, IP and operations. (Proceeds raised will be allocated as follows: 45% - R&D, 45% - Operations, 5% - AI Development, 5% - Patent Costs)

Globally, we are in a massive health crisis. Maxwell is poised to take a leadership position in pharmaceutical, cosmetics innovation and wellness industries. This company focuses on doing one thing, and one thing only -- innovating new molecules and selling them into large distribution partnerships. We are looking for investors that want to make a lasting, monumental impact in the world. Every investment on this page goes straight toward getting Claromers® out of the lab and into the hands of the doctors and patients who need them most. So much is at stake. The fate of billions rests on this work being completed. We'd love to have you with us; to change the face of healthcare forever. Invest what you can and help be part of our vision; to create health for the world, safely and affordably.

Scotch McClure

Founder, CEO and Chairman, Maxwell Biosciences

ॐ सर्वे सन्तु निरामयाः।


Downloads

Overview